Harrow announced the successful acquisition of Melt Pharmaceuticals, a clinical-stage company focusing on non-opioid sedation therapies.
Melt's groundbreaking product candidates, MELT-210, MELT-300, and MELT-400, utilize a unique oral dissolving tablet drug delivery platform, Zydis® ODT.
The acquisition expands Harrow's portfolio and solidifies its dedication to innovative therapies for enhanced patient outcomes in various medical settings.
Strategic Expansion
The acquisition of Melt Pharmaceuticals enhances Harrow's position in the multi-billion-dollar procedural sedation and anxiety market.
Innovative Sedation Solutions
MELT-300, a potential FDA-approved product, offers rapid and predictable sedation without intravenous administration, addressing the need to reduce opioid exposure.
Commercial Potential
MELT-210, another key drug candidate, presents strong commercial potential with advantages such as rapid uptake and a short half-life.
- The acquisition positions Harrow to revolutionize patient experiences in sedation across diverse medical specialties.
- MELT-300's innovative sedation approach has the potential to reduce opioid exposure and provide safer sedation alternatives for medical procedures.
Harrow's completion of the Melt Pharmaceuticals acquisition marks a significant milestone in advancing non-opioid sedation solutions for improved patient care and outcomes.